$0.93
+0.09
(+10.71%)▲
Live
12.26%
Downside
Day's Volatility :14.11%
Upside
2.12%
34.41%
Downside
52 Weeks Volatility :88.45%
Upside
82.39%
Period | Biofrontera Inc | Index (Russel 2000) |
---|---|---|
3 Months | -16.83% | 0.0% |
6 Months | -41.87% | 0.0% |
1 Year | -78.18% | 0.0% |
3 Years | -99.05% | -23.0% |
Market Capitalization | 4.2M |
Book Value | $2.14 |
Earnings Per Share (EPS) | -2.74 |
Wall Street Target Price | 11.5 |
Profit Margin | -38.34% |
Operating Margin TTM | -64.69% |
Return On Assets TTM | -40.24% |
Return On Equity TTM | -149.41% |
Revenue TTM | 35.2M |
Revenue Per Share TTM | 11.57 |
Quarterly Revenue Growth YOY | 34.0% |
Gross Profit TTM | 13.5M |
EBITDA | -18.3M |
Diluted Eps TTM | -2.74 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.21 |
EPS Estimate Next Year | -0.86 |
EPS Estimate Current Quarter | -0.77 |
EPS Estimate Next Quarter | -0.72 |
What analysts predicted
Upside of 1136.56%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 26.2M | - |
Net Income | -11.0M | - |
Net Profit Margin | -41.95% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 18.8M | ↓ 28.01% |
Net Income | -11.0M | ↑ 0.05% |
Net Profit Margin | -58.29% | ↓ 16.34% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 24.1M | ↑ 27.86% |
Net Income | -37.7M | ↑ 243.25% |
Net Profit Margin | -156.49% | ↓ 98.2% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 28.7M | ↑ 18.98% |
Net Income | -640.0K | ↓ 98.3% |
Net Profit Margin | -2.23% | ↑ 154.26% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 34.1M | ↑ 18.82% |
Net Income | -20.1M | ↑ 3045.47% |
Net Profit Margin | -59.09% | ↓ 56.86% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 8.7M | ↓ 13.91% |
Net Income | -7.5M | ↑ 168.51% |
Net Profit Margin | -85.63% | ↓ 58.18% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 5.8M | ↓ 33.04% |
Net Income | -9.8M | ↑ 31.55% |
Net Profit Margin | -168.21% | ↓ 82.58% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 8.9M | ↑ 51.83% |
Net Income | -6.3M | ↓ 35.53% |
Net Profit Margin | -71.43% | ↑ 96.78% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 10.6M | ↑ 19.34% |
Net Income | 3.5M | ↓ 155.6% |
Net Profit Margin | 33.28% | ↑ 104.71% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 7.9M | ↓ 25.43% |
Net Income | -10.4M | ↓ 396.0% |
Net Profit Margin | -132.1% | ↓ 165.38% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 7.8M | ↓ 0.78% |
Net Income | -257.0K | ↓ 97.54% |
Net Profit Margin | -3.28% | ↑ 128.82% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 28.8M | - |
Total Liabilities | 58.9M | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 24.1M | ↓ 16.05% |
Total Liabilities | 18.3M | ↓ 68.93% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 53.2M | ↑ 120.48% |
Total Liabilities | 41.9M | ↑ 128.73% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 50.9M | ↓ 4.39% |
Total Liabilities | 27.0M | ↓ 35.52% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 27.9M | ↓ 45.11% |
Total Liabilities | 23.1M | ↓ 14.32% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 42.0M | ↓ 17.53% |
Total Liabilities | 25.2M | ↓ 6.63% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 36.9M | ↓ 12.06% |
Total Liabilities | 29.7M | ↑ 17.92% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 34.1M | ↓ 7.59% |
Total Liabilities | 33.1M | ↑ 11.21% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 27.9M | ↓ 18.1% |
Total Liabilities | 23.1M | ↓ 30.02% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 24.6M | ↓ 12.02% |
Total Liabilities | 30.0M | ↑ 29.61% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 21.6M | ↓ 12.21% |
Total Liabilities | 10.7M | ↓ 64.45% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -37.7M | - |
Investing Cash Flow | 25.4M | - |
Financing Cash Flow | 16.4M | - |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -12.4M | ↓ 67.17% |
Investing Cash Flow | -11.0K | ↓ 100.04% |
Financing Cash Flow | 13.2M | ↓ 19.55% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -26.7M | ↑ 115.98% |
Investing Cash Flow | -11.0K | ↑ 0.0% |
Financing Cash Flow | 43.2M | ↑ 227.35% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -16.2M | ↓ 39.36% |
Investing Cash Flow | -5.2M | ↑ 46772.73% |
Financing Cash Flow | 14.0M | ↓ 67.54% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -3.7M | ↓ 55.4% |
Investing Cash Flow | 178.0K | ↓ 108.53% |
Financing Cash Flow | 1.1M | ↓ 111.78% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -10.3M | ↑ 180.18% |
Investing Cash Flow | 178.0K | ↑ 0.0% |
Financing Cash Flow | 1.1M | ↑ 0.0% |
Sell
Neutral
Buy
Biofrontera Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Biofrontera Inc | -34.88% | -41.87% | -78.18% | -99.05% | -99.05% |
Neurocrine Biosciences Inc. | 0.22% | -11.71% | 9.36% | 13.47% | 21.32% |
Haleon Plc Spon Ads | -5.08% | 20.69% | 22.01% | 36.17% | 36.17% |
Zoetis Inc. | -0.16% | 32.8% | 16.08% | -7.35% | 52.85% |
Viatris Inc. | 2.53% | 4.53% | 31.84% | -16.06% | -28.03% |
Catalent, Inc. | 0.9% | 7.56% | 42.8% | -54.43% | 23.98% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Biofrontera Inc | NA | NA | NA | -3.21 | -1.49 | -0.4 | NA | 2.14 |
Neurocrine Biosciences Inc. | 35.55 | 35.55 | 0.27 | 4.54 | 0.16 | 0.12 | NA | 24.87 |
Haleon Plc Spon Ads | 32.52 | 32.52 | 1.5 | 0.39 | 0.07 | 0.04 | 0.02 | 1.82 |
Zoetis Inc. | 37.9 | 37.9 | 2.64 | 5.83 | 0.49 | 0.14 | 0.01 | 10.94 |
Viatris Inc. | 224.4 | NA | 0.07 | 2.67 | -0.03 | 0.03 | 0.04 | 16.36 |
Catalent, Inc. | 211.02 | NA | 3.02 | 0.2 | -0.25 | 0.0 | NA | 19.91 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Biofrontera Inc | Buy | $4.2M | -99.05% | NA | -38.34% |
Neurocrine Biosciences Inc. | Buy | $11.9B | 21.32% | 35.55 | 16.0% |
Haleon Plc Spon Ads | Buy | $45.6B | 36.17% | 32.52 | 9.66% |
Zoetis Inc. | Buy | $87.6B | 52.85% | 37.9 | 26.29% |
Viatris Inc. | Hold | $14.0B | -28.03% | 224.4 | -4.24% |
Catalent, Inc. | Hold | $10.9B | 23.98% | 211.02 | -23.81% |
Insights on Biofrontera Inc
Revenue is down for the last 3 quarters, 10.59M → 7.83M (in $), with an average decrease of 13.1% per quarter
Netprofit is up for the last 2 quarters, -10.43M → -257.0K (in $), with an average increase of 3961.1% per quarter
In the last 1 year, Catalent, Inc. has given 43.0% return, outperforming this stock by 122.2%
Rosalind Advisors, Inc.
AIGH Capital Management, LLC
Scotia Capital Inc
Geode Capital Management, LLC
Tower Research Capital LLC
UBS Group AG
biofrontera pharma gmbh is a pharmaceuticals company based out of 104 waldhofer straße, heidelberg, bw, germany.
Organization | Biofrontera Inc |
Employees | 83 |
CEO | Dr. Hermann Luebbert Ph.D. |
Industry | Miscellaneous |
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$0.93
+10.71%
Invesco Bulletshares 2025 Hi
$0.93
+10.71%
Schwab International Dividend Equity Etf
$0.93
+10.71%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$0.93
+10.71%
Lightpath Technologies Inc
$0.93
+10.71%
Vaneck Vectors Global Alternative Energy Etf
$0.93
+10.71%
First Trust Flexible Municipal High Income Etf
$0.93
+10.71%
Drx Dly Reg Bank Bull 3x
$0.93
+10.71%
Graniteshares 2x Long Pltr Daily Etf
$0.93
+10.71%